<DOC>
	<DOCNO>NCT01724723</DOCNO>
	<brief_summary>Hepatitis anti-tuberculous treatment ( HATT ) obstacle manage TB patient , especially viral hepatitis . A previous study reveal risk HATT significantly high TB patient high serum hepatitis B virus ( HBV ) DNA level low HBV DNA level . Based finding , thus hypothesize risk HATT TB patient high baseline serum HBV DNA level reduce concomitant use anti-HBV agent . In proposal , conduct prospective randomize clinical study ass reduction HATT risk use entecavir TB patient high baseline serum HBV DNA level , evaluate risk treatment-related adverse event two hospital .</brief_summary>
	<brief_title>Using Entecavir Reduce Hepatitis Highly Viremic HBV Patients During Anti-tuberculous Treatment</brief_title>
	<detailed_description>Tuberculosis ( TB ) remain one important infectious disease worldwide . Timely implementation optimize anti-tuberculous therapy still mainstay prevent transmission TB . However , hepatitis anti-tuberculous treatment ( HATT ) obstacle manage TB patient , especially viral hepatitis . A previous study reveal risk HATT significantly high TB patient high serum hepatitis B virus ( HBV ) DNA level low HBV DNA level ( 39 % vs. 11 % ) , latter case similar risk HATT without viral hepatitis ( 14 % ) . Based finding , thus hypothesize risk HATT TB patient high baseline serum HBV DNA level reduce concomitant use anti-HBV agent . In proposal , conduct prospective randomize clinical study ass reduction HATT risk use entecavir TB patient high baseline serum HBV DNA level , evaluate risk treatment-related adverse event two hospital . From January 2012 June 2014 , subject culture-confirmed TB age 18 80 high serum HBV viral load prior anti-tuberculous treatment enrol randomize either study control group . High serum HBV viral load define &gt; 20,000 &gt; 2,000 IU/mL HBeAg-positive HBeAg-negative subject , respectively . In addition standard anti-tuberculous treatment , subject study group receive entecavir ( BARACLUDEÂ® ) 0.5 mg per day anti-tuberculous treatment 6 month stop anti-tuberculous treatment . Hemogram , liver function , renal function , serum HBV viral load regularly monitor detect development HATT adverse event . In study , HATT define fulfil anyone follow condition : ( 1 ) increase serum AST and/or ALT level &gt; 3 time upper limit normal ( ULN ) symptom baseline liver function normal ; ( 2 ) increase serum AST and/or ALT level &gt; 5 time ULN without symptom baseline liver function normal ; ( 3 ) increase serum AST and/or ALT level &gt; 2 time baseline baseline liver function abnormal ; ( 4 ) increase serum total bilirubin level &gt; 2.5 mg/dL .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>cultureconfirmed tuberculosis serologyconfirmed chronic HBV infection without flareup present ( IgM AntiHBcnegative either HBsAgpositive AntiHBcpositive ) high serum HBV viral load , define &gt; 20,000 &gt; 2,000 IU/mL HBeAg positive HBeAg negative patient , respectively serum AST and/or ALT level &lt; 2 time ULN serum level total bilirubin &lt; 2.0 mg/dL willing receive directly observe therapy , short course ( DOTs ) Target Disease Exceptions : human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis D virus ( HDV ) coinfection , multidrugresistant tuberculosis ( define simultaneous resistant isoniazid rifampin ) Medical History Concurrent Diseases 1. . ever receive antiviral therapy HBV 2. . alcoholism presence hepatic disease hepatitis B 3. . life expectancy le 1 year Sex Reproductive Status 1. . Pregnancy 2. . Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>hepatitis anti-tuberculous treatment</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>viral load</keyword>
	<keyword>entecavir</keyword>
</DOC>